Life sciences companies operate global businesses with global production sites and long, multifaceted development processes and post-marketing phases. As drugs are chemical compounds and potentially lethal, finalised drugs have to be approved by the authorities according to stringent compliance rules in various countries and continuously monitored to ensure on-going compliance.
MotivesThe clients' motives for improving drug development systems are typically to improve productivity, minimise non-compliance incidents and ensure adherence to GxP and GAMP5 which will make FDA and EMA audits a breeze.
OfferingsOur offerings range from advice on regulatory affairs in all aspects of the value chain, guidance on how to optimise business processes while remaining compliant to monitoring of regulatory requirements and help preparing for inspections.
Fill in the fields below and click send